Merck & Co., Inc.
Close on Oct 19, 2026
- Market cap
- $354.77B
- P/E (TTM)
- 114.9
- Dividend yield
- 2.28%
About Merck
Pharmaceutical Preparations, SIC 2834
Merck & Co., Inc. is a global healthcare company that provides prescription medicines, biologic therapies, vaccines, and animal health solutions. Its business is managed across two operating segments: Pharmaceutical and Animal Health. The Pharmaceutical division supplies human therapeutics and vaccines across oncology, hospital acute care, cardiometabolic conditions, virology, and diabetes to drug wholesalers, retailers, hospitals, government agencies, and physicians. The Animal Health segment delivers veterinary medications, vaccines, and digital identification and monitoring technologies for livestock and companion animals to veterinarians, distributors, farmers, and pet owners.
Merck operates globally with commercial presence and regulatory approvals across multiple regions, including the United States, Europe, China, and Japan. The company partners with international research and commercialization allies to develop and distribute products across worldwide markets. The provided text does not state the company's headquarters location or a specific count of operating facilities or countries.
Summary of the business section of Merck's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Merck & Co., Inc.
- Founded
- 1891
- Headquarters
- Rahway, NJ
- Address
- 126 East Lincoln Avenue, P.O. Box 2000 07065
- Phone
- (908) 740-4000
- Website
- www.msd.no
- Employees
- 75,000, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- New Jersey
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- MRK
- Exchange
- NYSE
- Shares outstanding
- 2.47B, Jul 31, 2026
- Public float
- $198.05B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Feb 17, 1999; 3-for-1, May 26, 1992; 3-for-1, May 26, 1988; 2-for-1, May 27, 1986; 2-for-1, Jun 1, 1972; 3-for-1, May 27, 1964
- SEC CIK
- 310158
- CUSIP
- 58933Y105
- ISIN
- US58933Y1055
- LEI
- 4YV9Y5M8S0BRK1RP0397
- EIN
- 22-1918501
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert M. Davis | Chairman, CEO & President, Director | 450,351 |
| Gaurav K. Gupta | EVP, CIDO | 750 |
| Chirfi Guindo | EVP, Access, Policy & Comms | 36,670 |
| Jennifer Zachary | EVP, General Counsel | 125,824 |
| Richard R. DeLuca | EVP&Pres, Merck Animal Heallth | 111,488 |
| David R. Maraldo | EVP & Pres. MMD | 29,258 |
| David Michael Williams | EVP,Chief Info&Digital Officer | 31,716 |
| Dalton E. Smart III | SVP Fin. - Global Controller | 9,388 |
| Brian Foard | EVP, Specialty, Pharma, & ID | – |
| Dean Y. Li | Executive VP & President, MRL | 94,431 |
| Johannes Jacobus Oosthuizen | EVP, Oncology & Int?l | 21,895 |
| Betty D. Larson | EVP, Chief HR Officer | 13,774 |
| Caroline Litchfield | EVP & CFO | 92,301 |
| Sanat Chattopadhyay | Exe V-P & Pres. MMD | 200,675 |
| Joseph Romanelli | President, Human Health Int?l | 28,739 |
| Cristal N. Downing | Chief Comm. & Public Afrs Ofcr | 0 |
| Mary Ellen Coe | Director | 10 |
| Surendralal Lanca Karsanbhai | Director | 1 |
| Christine E. Seidman | Director | 100 |
| Inge G. Thulin | Director | 2,933 |
| Pamela J. Craig | Director | 1,715 |
| Patricia F. Russo | Director | 13,148 |
| Kathy J. Warden | Director | 500 |
| Douglas M. Baker Jr | Director | 16,000 |
| Risa J. Lavizzo-Mourey | Director | 1,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.Davis | $20.80M | $15.76M | $6.92M | $158 | $198 |
| FY2024 Mr.Davis | $23.19M | $14.73M | $9.49M | $144 | $146 |
| FY2023 Mr.Davis | $20.27M | $26.70M | $7.63M | $154 | $134 |
| FY2022 Mr.Davis | $18.65M | $52.47M | $8.41M | $152 | $130 |
| FY2021 Mr.Davis | $13.72M | $14.39M | $6.71M | $102 | $122 |
| FY2021 Mr.Frazier | $15.20M | $13.33M | $6.71M | $102 | $122 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had approximately 75,000 employees worldwide, including approximately 30,000 people in the U.S., including Puerto Rico, and approximately 15,000 third-party contractors globally.”
Corporate history
Events identified from SEC filings